From the beginning, our mission has been clear: to transform clinical trials through technology and real-world data. We’re revolutionising the way trials are designed and delivered - driving innovation, enhancing patient safety, and accelerating the journey of life-changing treatments to market.
Our evolution has continued over the years since then, always guided by our core values of Respect, Honesty and Integrity, Teamwork, Innovation, and Trust.
With our commitment to driving measurable impact, innovation and optimising participant engagement, we have built seamless and scalable platforms that foster representation and inclusivity, ensuring clinical trials are more effective, safer and more accessible than ever before.
2010
Founded on our belief that technology could revolutionise clinical trials, we launched our FARSITE platform in 2010. This groundbreaking tool enabled researchers to identify and recruit patients more efficiently, marking our first step towards real-world data intelligence.
During this period, we also conducted the Salford Lung Study, the world’s first pre-licensed randomised controlled trial using real-world data. Carried out in collaboration with GSK, this significant achievement showcased our dedication to innovation and optimising participant engagement, ensuring that clinical research could be conducted efficiently in a real-world setting.
2016
By 2016 we had officially incorporated, and a year later, the launch of our ConneXon platform expanded our capabilities, supporting multiple concurrent studies over the coming years.
2017
2020
In 2020, FARSITE achieved proof of concept on secondary care data, strengthening its role in real-world data intelligence. Meanwhile, ConneXon evolved to manage multiple studies simultaneously, demonstrating seamless and scalable platform capabilities.
2021
The following year, we collaborated with Novartis to design and execute a Phase IIIB trial, successfully recruiting 900 eligible patients. This project reflected our commitment to effective teamwork, as it worked closely with partners to deliver meaningful clinical outcomes.
2022
We expanded into the US market in 2022, achieving proof of concept for FARSITE on US (OM1) data, further advancing our real-world data intelligence expertise.
2024
We then introduced Serious Adverse Event (SAE) reporting in 2024 and the auto-population of SAE forms within ConneXon, enhancing efficiency while maintaining the highest standards of trust. We also launched a solution in FARSITE for identifying participants using deprivation scores (IMD Index).
2024
As we head into the future, our dedication to innovation and driving measurable impact is stronger than ever. Our new pilot initiative with CPRD shows us continuing to push boundaries in clinical trial optimisation, with access to a data set of over 20 million patients.
2024
With trust, collaboration and a pioneering spirit at our heart, we are not just shaping the future of clinical trials – we are redefining them with a clear mission to accelerate healthcare developments, and champion diversity and inclusion to deliver actionable insights that improve patient outcomes.
